Dr. Andre Posner Featured in In-Depth Online Interview Highlighting His Legacy in Medicine and Medical Education
The feature explores topics ranging from his upbringing in a multigenerational home in Merion Station, Pennsylvania, to the profound influence of his father's work eradicating smallpox in Africa during his early years in Dakar, Senegal. It also delves into his teaching style, the evolving landscape of healthcare, and the importance of mindfulness, strategic thinking, and empathy in both medicine and life.
In the interview, Dr. Posner shares deeply personal reflections and hard-earned wisdom gained from decades of clinical practice at institutions including Frankford Hospital, Main Line Health, and Penn Medicine. Readers will gain insight into the values that guide his work: trust, clarity, adaptability, and presence.
'This was an opportunity to speak not just as a doctor, but as a human being shaped by patients, mentors, and life itself,' said Dr. Posner. 'I'm grateful to share my story and, hopefully, inspire others in the field to lead with empathy and intention.'
Dr. Posner's feature is part of a broader effort to spotlight voices in medicine who are making a difference not only through clinical excellence but also through education, mentorship, and compassion.
To read the full article, visit the website here.
About Dr. Andre Posner:
Dr. Andre Posner is an award-winning physician and educator known for his commitment to patient care and medical mentorship. With over two decades of hospitalist experience and numerous teaching honors—including the D. Stratton Woodruff Award and Faculty Award for Resident Teaching—Dr. Posner continues to be a guiding force in medicine. He is currently affiliated with Penn Medicine and remains active in both clinical practice and medical education.
Media Contact
Contact Person: Andre Posner
Email: Send Email
City: Philadelphia
State: Pennsylvania
Country: United States
Website: https://www.drandreposner.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 days ago
- CTV News
9-year-old dies after incident at Hersheypark's water park in Pennsylvania
The Boardwalk at Hersheypark in Hershey, Pennsylvania, on Friday, July 6, 2007. (Max W. Orenstein/Allentown Morning Call/Tribunevia CNN Newsource) A 9-year-old child passed away after an incident at Hersheypark's water park Thursday night in Pennsylvania, according to the company's CEO. Hershey Entertainment CEO John Lawn said a lifeguard team recognized a child 'was in distress' and performed an 'immediate rescue,' followed by 'continuous, coordinated life-saving efforts by our lifeguards, on-site first responders, and medical personnel,' according to a statement post on the park's Facebook. 'The child was transported without delay to Milton S. Hershey Medical Center, where despite everyone's tireless efforts, the child did not recover,' Lawn's statement said. The company did not say the cause of the child's death. 'Our hearts break for this child and the child's family. We extend our deepest condolences for their loss,' the statement said, adding that it would not release personal details at this time. The company said that it will conduct a 'thorough internal review' in the coming days and 'cooperate fully with authorities.' The water park – The Boardwalk at Hersheypark – features 16 water attractions. The 119-year-old amusement park in Hershey, Pennsylvania, opened its water park in 2007. 'To every family that visits Hersheypark, please know this: your safety and well-being drive every decision we make. We will thoroughly investigate this tragedy and honor the memory of this young guest by continuing our focus on ensuring the safety of our guests at Hersheypark,' the CEO added. By Alex Stambaugh, CNN
Globe and Mail
6 days ago
- Globe and Mail
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ('Coeptis' or the 'Company'), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd ('Yorkville'). The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company's outstanding debt obligations to Yorkville. David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, 'The extinguishment of these outstanding debt obligations strengthens the Company's capital structure and positions us well to pursue our long-term goals.' Management notes that a streamlined capital structure free from the weight of unnecessary outstanding obligations will help the Company navigate its proposed strategic addition of operations in the cryptocurrency space. About Coeptis Therapeutics Holdings COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts. The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute. Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency. Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit No Offer or Solicitation This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination or spin out. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom Cautionary Note Regarding Forward-Looking Statements. This press release and statements of our management made in connection therewith contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission (the "SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Globe and Mail
17-07-2025
- Globe and Mail
Dr. Edward Lubin Announces Nationwide Opportunity for Future Medical Leaders Through Newly Launched Scholarship Initiative
Tampa, FL - Dr. Edward Lubin, a respected figure in the field of interventional pain medicine, is proud to introduce the Dr. Edward Lubin Scholarship for Medical Students, a national academic opportunity designed to identify and support the next generation of healthcare professionals. Open to undergraduate students across the United States, this scholarship aims to recognize students who are committed to improving healthcare through innovation, compassion, and a deep sense of purpose. Hosted through the official scholarship website at the program invites applicants to submit a brief yet meaningful essay that reflects their personal aspirations in medicine and how they plan to contribute to the evolving landscape of healthcare. This annual initiative is founded and overseen by Dr. Edward Lubin, a physician whose career has spanned neuroscience research, surgical training, and pain medicine. Through his own academic and clinical journey, Dr. Edward Lubin has come to understand that true change in medicine begins not only with knowledge and skill, but with vision and dedication. The scholarship reflects this belief by offering students a platform to share their goals and values, while also receiving recognition for their dedication to the future of healthcare. Eligibility Criteria To qualify, applicants must currently be enrolled as undergraduate students in the United States and must demonstrate a clear interest in pursuing a career in medicine or a related healthcare field. Central to the application process is the submission of an original essay in response to the following prompt: In 500 words or less, describe how you hope to use your medical education to make a meaningful impact on the future of healthcare. What personal experiences or goals drive your passion for medicine, and how do you envision your role in improving the lives of others? The deadline to apply for the Dr. Edward Lubin Scholarship for Medical Students is April 15, 2026, with the selected recipient to be announced on May 15, 2026. Dr. Edward Lubin created this scholarship not just as a financial award but as a meaningful opportunity to uplift those who show an early commitment to service and scientific inquiry. His belief in building a foundation for future physicians is rooted in his own experiences in both academic and clinical settings. The scholarship also reflects Dr. Edward Lubin's long-standing commitment to patient advocacy and medical education. With a vision to cultivate leadership in medicine, Dr. Edward Lubin invites students to bring forth their stories, goals, and inspirations—allowing their voices to be heard as part of a broader movement toward a more compassionate and effective healthcare system. This scholarship is not bound by geographic location and is open to undergraduate applicants from all regions across the United States. For full details, eligibility requirements, and essay submission guidelines, please visit the official website: Media Contact Company Name: Dr. Edward Lubin Scholarship for Medical Students Contact Person: Dr. Edward Lubin Email: Send Email City: Tampa State: Florida Country: United States Website:
